Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Completed · Phase 1/Phase 2
Conditions studied: Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
In brief
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+ lymphomas).
Key facts
- Study ID
- NCT03397706
- Run by
- Viracta Therapeutics, Inc.
- People needed
- 64
- Starts
- 2018-03-29
- Expected to finish
- 2023-05-04
- Last updated by the study team
- 2025-03-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
- University of California, Los Angeles — Los Angeles, California, United States
- UC Irvine Chao Family Comprehensive Cancer Center — Orange, California, United States
- University of Colorado Anschutz Cancer Pavilion — Aurora, Colorado, United States
- Mid Florida Hematology and Oncology Center — Orange City, Florida, United States
- ASCLEPES Research Centers — Weeki Wachee, Florida, United States
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
- Georgia Cancer Center at Augusta University — Augusta, Georgia, United States
- Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
- Ruth M Rothstein CORE Center — Chicago, Illinois, United States
- Indiana Blood and Marrow Transplantation — Indianapolis, Indiana, United States
- The University of Kansas Cancer Center and Medical Pavilion — Westwood, Kansas, United States
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- St. Vincent Healthcare Cancer Center — Billings, Montana, United States
- John Theurer Cancer Center at Hackensack UMC — Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Weill Cornell Medical College - New York Presbyterian Hospital — New York, New York, United States
- The Ohio State University Wexner Medical Center James Cancer Hospital — Columbus, Ohio, United States
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Texas Oncology - Baylor Sammons Cancer Center — Dallas, Texas, United States
- Centro de Hematologia e Oncologia da Bahia (CEHON) — Salvador, Estado de Bahia, Brazil
- Hospital de Cancer de Pernambuco (HCP) — Recife, Pernambuco, Brazil
- Hospital do Cancer Mae de Deus — Porto Alegre, Rio Grande do Sul, Brazil
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.